New Strategy to Quantify Hepatic CYP3A Activity with Deoxyschizandrin as an In Vivo Probe: A Vmax, app Approach
DOI:
文献链接: 10.1016/j.dmd.2026.100248
其他信息:
X Li, C Hu, G Wei, T Chen, J Tao, J Wu…
Drug Metabolism and …, 2026
Elsevier
Inter-individual variability in drug response stems largely from metabolic enzyme activity differences, with cytochrome P450 3A (CYP3A) being the predominant enzyme whose fluctuations critically impact exposure to narrow-therapeutic-index drugs (eg, tacrolimus) and anticancer agents. Current clinical probes like midazolam (suboptimal hepatic uptake, sedation) and the erythromycin breath test (poor selectivity) remain inadequate. This study proposes deoxyschizandrin (DS), derived from Schisandra chinensis, as a novel in vivo …

